Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAX576 · 7 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| QAX576 | EXPERIMENTAL | - |
| Infliximab | OTHER | - |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| QAX576 1 mg/kg | ACTIVE_COMPARATOR | - |
| QAX576 3 mg/kg | ACTIVE_COMPARATOR | - |
| QAX576 10 mg/kg | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| QAX576 | DRUG | - |
| Infliximab | DRUG | - |
| Placebo | DRUG | every 3 weeks via intravenous infusion |
| QAX576 placebo | DRUG | - |
Inclusion Criteria: * At least one draining enterocutaneous perianal fistula * Diagnosis of Crohn's disease (CD) must have been established for at least 6 months * At least one ineffective fistula treatment (but no previously failed anti-TNFα (tumour necrosis factor) antibody treatment) * Patients ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
QAX576 is an investigational small molecule being studied for several conditions, including Crohn's Disease, Eosinophilic Esophagitis, Idiopathic Pulmonary Fibrosis, Asthma, and Allergic Rhinitis. It has been evaluated in clinical trials for these indications, though it is not approved and remains in clinical development.
QAX576 is developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. Novartis has sponsored clinical trials of QAX576 across multiple therapeutic areas.
QAX576 has been studied in Phase 2 clinical trials for conditions such as Idiopathic Pulmonary Fibrosis, Allergic Rhinitis, and Crohn's Disease, and in a Phase 1 trial for Asthma. All known trials are completed, and the drug remains investigational.
QAX576 has been evaluated in several completed trials, including NCT00532233 in Idiopathic Pulmonary Fibrosis, NCT00584584 in Allergic Rhinitis, NCT00940160 in Asthma, and NCT01355614 in fistulizing Crohn's Disease. These trials were placebo-controlled and double-blind.
QAX576 is described in a clinical trial title as an interleukin-13 monoclonal antibody, specifically in a study of simulated hayfever. This suggests it targets interleukin-13, though the drug is also classified as a small molecule in other contexts.